Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. - Meyers PA; Federman N; Daw N; Anderson PM; Davis LE; Kim A; Macy ME; Pietrofeso A; Ratan R; Riedel RF; Trucco M; Breitmeyer JB; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024)